ClinicalTrials.gg
Not yet recruitingNCT07403864Updated Feb 11, 2026

Effects of Acute Sleep Deprivation on Health

An interventional study of Normal sleep and Partial sleep deprivation in Glucose Intolerance, Energy Expenditure and Vascular Stiffness, sponsored by National Taiwan Normal University. Not yet recruiting. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by National Taiwan Normal University · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

This study will investigate whether various types of regular exercise can provide protective effects against metabolic abnormalities induced by sleep restriction. It will examine responses related to metabolic health, cognitive function, energy expenditure, subjective feelings, and human behaviors, including physical activity and energy intake.

Read the detailed description

Sleep disturbances are common among the Taiwanese population due to work-related stress, shift work, and academic demands. Poor sleep can impair glucose and lipid metabolism, increasing the risk of cardiovascular disease and type 2 diabetes. This study will investigate whether regular exercise can mitigate these adverse effects. The findings aim to inform diverse exercise intervention strategies tailored to different populations to reduce health risks associated with insufficient sleep.

Participants will be healthy adults aged 20 to 45, categorized according to their habitual activity levels.

  1. Sedentary: fewer than 7,000 steps per day and no regular exercise in the past 6 months.
  2. Regular Aerobic Exercise: Running or cycling at least 2-3 times per week for the past 6 months.
  3. Regular Resistance Exercise: Resistance training performed at least 2-3 times per week for the past 6 months, with minimal aerobic training.

Eligible participants must have regular sleep habits (Pittsburgh Sleep Quality Index [PSQI] ≤ 5), stable body weight (±3% over the past 3 months), no chronic diseases, no smoking or drinking habits, and no special diets.

Prior to the first main trial, participants will complete assessments of V̇O2max and maximal muscle strength within 7 to 14 days before the main trials. They will also record one week of daily physical activity, sleep patterns (including bedtime and wake-up times), and diet (covering two weekdays and one weekend day) to ensure they meet the inclusion criteria.

Day 1:

Physical activity will be restricted to a minimum, with no exercise permitted. Participants may eat freely before 15:00; however, all food intake will be recorded to enable replication prior to the second main trial. Napping is not allowed. Participants will arrive at the laboratory between 18:30 and 19:00. Upon arrival, after a 20-minute rest period, baseline measurements will be conducted, including body composition, waist and hip circumference, vascular function, subjective questionnaires, heart rate variability, food preference, a 20-minute energy metabolism assessment, and cognitive function testing. Subsequently, a standardized dinner will be provided by the researchers and consumed within 25 minutes. Participants will be allowed to wash and prepare between 20:00 and 20:30. From arrival onward, participants will remain seated on the experimental bed throughout the entire laboratory session. Continuous Glucose Monitoring (CGM) will be installed on day 1. Participants will have either an 8-hour sleep opportunity in the laboratory from 23:00 to 07:00 (i.e., normal sleep trial) or a 3-hour sleep opportunity from 03:00 to 07:00 (i.e., partial sleep deprivation trial).

Day 2:

Participants will wake at 07:00. After completing personal hygiene, they will rest for 20 minutes to ensure full wakefulness. At 07:30, a 20-minute resting metabolic rate assessment will be conducted, alongside the collection of heart rate variability and muscle oxygen saturation data. Subsequently, pulse wave velocity measurement, cognitive function tests, and subjective questionnaires will be administered.

This will be followed by a 3-hour oral glucose tolerance test (OGTT), during which 75 g of glucose will be ingested, and muscle oxygen saturation will be continuously monitored. Capillary blood samples will be collected via finger prick at 0, 30, 60, 90, 120, 150, and 180 minutes, alongside continuous glucose monitoring. Resting gas exchange, heart rate variability, and pulse wave velocity will be measured every 60 minutes. Blood pressure and visual analogue scale assessments-including sleep, appetite, and mood-will be recorded every 30 minutes. Cognitive function will be evaluated every 90 minutes.

Upon leaving the laboratory, participants will receive a pedometer and wearable devices. They will be instructed to record their dietary intake (using a food scale and photographic records), sleep patterns, and glucose levels on the experimental day and for the subsequent four consecutive days.

02

Conditions studied

  • Glucose Intolerance
  • Energy Expenditure
  • Vascular Stiffness
  • Cognition

Keywords

  • Partial sleep deprivation
  • Sleep loss
  • Physical inactivity
  • Exercise habits
03

In context

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 113 are open to participants now.

This study's planned enrollment of 48 is below the median of 56 across 660 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

National Taiwan Normal University is the lead sponsor of 64 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 20-45 years.
  • (BMI) between 18.5-27 kg/m².
  • No sleep-related medical conditions and good sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≤ 5.
  • Usual bedtime between 22:00-01:00, wake-up time between 06:00-09:00, with an average sleep duration of 7 to 9 hours; chronotype classified as "definitely not evening type" (score ≥ 42 on the Morningness-Eveningness Questionnaire), and no changes in sleep patterns over the past 3 months.
  • Without any metabolic or cardiovascular diseases, and not using medications that could affect metabolic responses.
  • No specific dietary habits, such as intermittent fasting or a ketogenic diet.
  • Maintaining a stable weight (no self-reported weight change ± 3 kg) for at least 3 months.
  • Resting blood pressure ≤ 130/80 mmHg.
  • No smoking or excessive alcohol consumption.
  • Not a shift worker.
  • No international travel across time zones has occurred within the past 3 months.

Exclusion criteria

Exclusion Criteria:

  • Special diets (e.g., intermittent fasting, ketogenic diet)
  • Recent injuries or to intense exercise.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Normal sleep

    Participants will have an 8-hour sleep opportunity in the lab from 23:00 to 07:00.

    Behavioral: Normal sleep

  • Experimental
    Partial sleep deprivation

    Participants will have a 3-hour sleep opportunity in the lab from 03:00 to 07:00.

    Behavioral: Partial sleep deprivation

Interventions

  • BehavioralNormal sleep

    Participants will have an 8-hour sleep opportunity in the lab from 23:00 to 07:00.

  • BehavioralPartial sleep deprivation

    Participants will have a 3-hour sleep opportunity in the lab from 03:00 to 07:00.

06

What researchers measure

Primary outcomes

  1. Glycemic Control

    Glucose responses during the 3-hour oral glucose tolerance test (OGTT)

    Time frame: Baseline measurements and continuously at regular intervals throughout the 3-hour OGTT.

  2. Pulse wave velocity (PWV)

    Pulse wave velocity assessments (i.e., meters per second) will be collected before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT

  3. Cognitive function (Accuracy)

    Accuracy (i.e., %) in computerized tests will be tested before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 (baseline), 90 and 180 minutes during OGTT

  4. Cognitive function (Reaction time)

    Reaction time (i.e., milliseconds) in computerized tests will be tested before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 (baseline), 90 and 180 minutes during OGTT

Secondary outcomes

  1. Resting energy expenditure

    Energy expenditure will be collected before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT

  2. Carbohydrate oxidation

    Carbohydrate oxidation will be collected before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT

  3. Fat oxidation

    Fat oxidation will be collected before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT

  4. Heart rate variability

    Heart rate variability will be collected before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 (baseline), 60, 120 and 180 minutes during OGTT

  5. Muscle oxygen saturation

    Muscle oxygen saturation data will be collected before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 minute (baseline) and throughout the entire 3-hour OGTT

  6. Blood pressure

    Blood pressure (mmHg) assessments will be collected before and during the 3-hour oral glucose tolerance test (OGTT).

    Time frame: 0 (baseline), 30, 60, 90, 120,150 and 180 minutes during OGTT

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 253 non-industry interventional studies with no phase under Glucose Intolerance, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 285 studies reached it within 26 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Feb 11, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07403864
Lead sponsor
National Taiwan Normal University
Responsible party
Yung-Chih Chen (Principal Investigator, National Taiwan Normal University) — Principal investigator
First posted
Feb 11, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Feb 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion